194 related articles for article (PubMed ID: 35462330)
1. Update of Indoles: Promising molecules for ameliorating metabolic diseases.
Hu W; Yan G; Ding Q; Cai J; Zhang Z; Zhao Z; Lei H; Zhu YZ
Biomed Pharmacother; 2022 Jun; 150():112957. PubMed ID: 35462330
[TBL] [Abstract][Full Text] [Related]
2. Hepatic Mediators of Lipid Metabolism and Ketogenesis: Focus on Fatty Liver and Diabetes.
Fernandes GW; Bocco BMLC
Curr Diabetes Rev; 2021; 17(7):e110320187539. PubMed ID: 33143628
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
[TBL] [Abstract][Full Text] [Related]
4. Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions.
Ore A; Akinloye OA
Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441028
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Effect of Curcumin on Metabolic Diseases: Evidence from Clinical Studies.
Zeng Y; Luo Y; Wang L; Zhang K; Peng J; Fan G
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834734
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
[TBL] [Abstract][Full Text] [Related]
7. Obstructive Sleep Apnea Syndrome and Metabolic Diseases.
Li M; Li X; Lu Y
Endocrinology; 2018 Jul; 159(7):2670-2675. PubMed ID: 29788220
[TBL] [Abstract][Full Text] [Related]
8. The Mechanism Underlying the Influence of Indole-3-Propionic Acid: A Relevance to Metabolic Disorders.
Zhang B; Jiang M; Zhao J; Song Y; Du W; Shi J
Front Endocrinol (Lausanne); 2022; 13():841703. PubMed ID: 35370963
[TBL] [Abstract][Full Text] [Related]
9. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
Thondam SK; Cuthbertson DJ; Wilding JPH
Peptides; 2020 Mar; 125():170208. PubMed ID: 31759125
[TBL] [Abstract][Full Text] [Related]
10. Metabolic liver disease in diabetes - From mechanisms to clinical trials.
Dewidar B; Kahl S; Pafili K; Roden M
Metabolism; 2020 Oct; 111S():154299. PubMed ID: 32569680
[TBL] [Abstract][Full Text] [Related]
11. [Incretins-adipocytokines interactions in type 2 diabetic subjects with or without non-alcoholic fatty liver disease: interest of GLP-1 (glucagon-like peptide-1) as a modulating biomarker].
Chellali S; Boudiba A; Griene L; Koceir EA
Ann Biol Clin (Paris); 2019 Jun; 77(3):261-271. PubMed ID: 30998190
[TBL] [Abstract][Full Text] [Related]
12. Neonatal overfeeding during lactation rapidly and permanently misaligns the hepatic circadian rhythm and programmes adult NAFLD.
Ribas-Aulinas F; Ribo S; Parra-Vargas M; Fernández-Pérez A; Cebrià J; Guardiola-Perello M; Ramon-Krauel M; Lerin C; Diaz R; Kalko SG; Vallejo M; Díez-Noguera A; Cambras T; Jimenez-Chillaron JC
Mol Metab; 2021 Mar; 45():101162. PubMed ID: 33422644
[TBL] [Abstract][Full Text] [Related]
13. Gut microbial metabolites in obesity, NAFLD and T2DM.
Canfora EE; Meex RCR; Venema K; Blaak EE
Nat Rev Endocrinol; 2019 May; 15(5):261-273. PubMed ID: 30670819
[TBL] [Abstract][Full Text] [Related]
14. Managing metabolic diseases: The roles and therapeutic prospects of herb-derived polysaccharides.
Xu X; Wang L; Zhang K; Zhang Y; Fan G
Biomed Pharmacother; 2023 May; 161():114538. PubMed ID: 36931026
[TBL] [Abstract][Full Text] [Related]
15. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis.
Finck BN
Diabetes; 2018 Dec; 67(12):2485-2493. PubMed ID: 30459251
[TBL] [Abstract][Full Text] [Related]
16. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.
Dhir G; Cusi K
J Investig Med; 2018 Jan; 66(1):7-10. PubMed ID: 28918389
[TBL] [Abstract][Full Text] [Related]
17. Biochanin A improves hepatic steatosis and insulin resistance by regulating the hepatic lipid and glucose metabolic pathways in diet-induced obese mice.
Park HS; Hur HJ; Kim SH; Park SJ; Hong MJ; Sung MJ; Kwon DY; Kim MS
Mol Nutr Food Res; 2016 Sep; 60(9):1944-55. PubMed ID: 27145114
[TBL] [Abstract][Full Text] [Related]
18. Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases.
Formichi C; Nigi L; Grieco GE; Maccora C; Fignani D; Brusco N; Licata G; Sebastiani G; Dotta F
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299336
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih M; Jornayvaz FR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
[TBL] [Abstract][Full Text] [Related]
20. Intestinal Fructose and Glucose Metabolism in Health and Disease.
Merino B; Fernández-Díaz CM; Cózar-Castellano I; Perdomo G
Nutrients; 2019 Dec; 12(1):. PubMed ID: 31905727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
